|
8.0
Dosage Modification Based on Toxicity - If multiple toxicities
are seen, administer dose based on greatest reduction required
for any single toxicity observed. Reductions or increases
apply to treatment given in the preceding cycle and are
based on toxicities observed since the prior dose. The following
are guidelines to be used
with clinical judgment. 
ALERT:
ADR reporting may be required for some toxicities. See Section
10.
Toxicity
| Agent
| Dosage
Change
|
|---|
Deep
venous thrombosis or pulmonary embolus
| Liquid
(Megace or placebo)
| Discontinue
liquid. Continue capsule.
|
Excessive
weight gain
(>120% ideal body weight as a subjective
guideline)
| Liquid
(Megace or placebo)
Capsule
(Marinol or placebo)
| Decrease
both by 50% or stop at MD discretion.
|
Unacceptable
weight loss after reducing or stopping dose
| Liquid
(Megace or placebo)
Capsule
(Marinol or placebo)
| Increase
both back to original dose at MD discretion.
|
Unacceptable
CNS toxicity
| Capsule
(Marinol or placebo)
| Decrease
dose by 50% or discontinue capsule per physician
discretion. Continue liquid.
|
|
Note:
All dose modification rationale should be clearly documented
on the flow sheet. When doses are modified for excessive
weight gain, the patient should still be followed per protocol.
|